AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06583889
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients randomized to standard medical care will receive (or continue) either any type of body-weight adjusted low molecular weight heparin in therapeutic dose, or intravenous adjusted dose unfractionated heparin (aPTT value kept within 1 time the normal value), according to the existing international guidelines.
Trial: NCT06622148
Drug: Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)
RxNorm normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) .
Trial: NCT06622148
Drug: Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)
RxNorm normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
Trial: NCT05416749
Drug: 8MW2311
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive a single intravenous (IV) infusion of 8MW2311 every 21 days (q21d), other dosing frequencies may be used.
Trial: NCT06696703
Drug: Human urinary kininogenase(HUK)
RxNorm normalized name: kininogenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (HUK plus routine clinical treatment): administered within 48 hours of AIS onset, 0.15PNA unit was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day.
Trial: NCT05541497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1-3: 0.5mg pill once per day, Days 4-7: 0.5mg pill twice per day, Weeks 2-8: 1mg pill twice per day
Trial: NCT05199194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of placebo, matching the volume of tenecteplase 0.25mg/kg
Trial: NCT04814511
Drug: InfectoScab 5 % Creme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
Trial: NCT06055777
Drug: SZEY-2108 for injetion
RxNorm normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part1（Single-dose intravenous infusion dose-escalation trial）:100mg，200mg，500mg, 1000mg, 2000mg，4000mg and the dose of last cohort to be determined. Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：1000mg at Q8h，2000mg at Q8h, and one dose level of 1000mg, 1500mg or 2000mg at Q6h. Multiple intravenous doses of SZEY-2108 at Q8h or Q6h on D1\~D7 and on the morning of D8.
Trial: NCT06055777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part1（Single-dose intravenous infusion dose-escalation trial）:250mL/500mL，Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：250mL,Multiple intravenous doses of placebo at Q8h or Q6h on D1\~D7 and on the morning of D8.
Trial: NCT06309043
Drug: recombinant anti-EGFR human/murine chimeric monoclonal antibody injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose，250 mg/m2
Trial: NCT05311475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray
Trial: NCT05245656
Drug: RB/RBAC alternating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to the RB alternating with RBAC arm will receive six cycles of alternating RB (odd cycles) or RBAC (even cycles)~RB (1st, 3rd, and 5th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 90mg/m2, IV, D1-2~RBAC (2nd, 4th, and 6th cycles)~* Rituximab 375mg/m2, IV, D1~* Bendamustine 70mg/m2, IV, D2-3~* Cytarabine 500mg/m2, IV, D2-4
Trial: NCT04756960
Drug: CHF6001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of \[14\^C\]-labelled CHF6001
Trial: NCT05494060
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
Trial: NCT06726876
Drug: Normal saline rinses.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: Patients will use 20 ml of normal saline.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the saline solution for a specified duration and avoid swallowing it.~Unique Elements:~Control Comparison: Provides a placebo comparison to evaluate the efficacy of the Manuka honey intervention.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm.
Trial: NCT05978661
Drug: FKC288
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of FKC288 Four dose groups of 0.1×10\^6 CAR-T/kg, 0.3×10\^6 CAR-T/kg, 1.0×10\^6 CAR-T/kg, and 3.0×10\^6 CAR-T/kg FKC288 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.
Trial: NCT04730947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally once a day, the placebo looks identical to the study drug but it contains no active ingredient
Trial: NCT06300398
Drug: IAMA-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAMA-6 liquid suspension
Trial: NCT06300398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-to-match IAMA-6 liquid suspension
Trial: NCT06454292
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and remifentanil was continuously pumped at a starting dose of 1.5ug/kg/h. The time of remifentanil initiation was recorded as T0. Subjects were assessed for sedation using the RASS score and analgesia using the CPOT score. We waited for the original sedative-analgesic drugs to elute until CPOT ≥ 3 and RASS \> 0. The infusion rate of remifentanil was adjusted according to the CPOT score (1.5ug/kg/h is recommended, the range of adjustment is 1.5\~12μg/kg/h, and the maximum infusion rate is not more than 12μg/kg/h) until the subject's analgesic score of CPOT\<3, and the interval between the two experimental rate adjustments of the drug should be ≧5min, and the CPOT score should be performed before each adjustment of the drug. The CPOT score should be performed before each drug adjustment.
Trial: NCT06500286
Drug: Marciane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A caudal block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
Trial: NCT06165926
Drug: 15% hypertonic dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The solution is prepared with 3 ml of 50% Dextrose, 1 ml of 2% xylocaine, and 6 ml of normal saline.~The ultrasound-guided injection of 15% hypertonic dextrose is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with hypertonic dextrose is performed at the fourth weeks. A total of 2 sessions of hypertonic dextrose injections are performed.
Trial: NCT06165926
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The solution is prepared with 1 ml of 2% xylocaine + 9 ml of normal saline. The ultrasound-guided injection of Normal saline(0.9%) is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with Normal saline is performed at the fourth weeks. A total of 2 sessions of Normal saline injections are performed.
Trial: NCT06306846
Drug: Immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 monoclonal antibody and TP chemotheapy
Trial: NCT04294836
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO Capsules 500mg
Trial: NCT04855266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)
Trial: NCT04984577
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection, one dose every 12 hours, continue for 14 days
Trial: NCT05356403
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken orally 1 time/day
Trial: NCT06445816
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Parents whose consent was obtained will be asked to fill out the Mother and Child Information Collection Form and Psychological Resilience Scale, respectively.~* Immediately after receiving chemotherapy, the pain levels of the children will be measured with the Facial Expressions Pain Scale - Faces Pain Scale-Revised (FPS-R).~* The psychological resilience scale will be applied to mothers.
Trial: NCT04642261
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical in appearance to empagliflozin 10mg daily
Trial: NCT06307093
Drug: Keytruda®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)
Trial: NCT05290740
Drug: Norepinephrine 5 mcg
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: norepinephrine bolus of 5 mcg for treatment of sever postspinal hypotension
Trial: NCT05290740
Drug: Norepinephrine 10 mcg
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: norepinephrine bolus of 10 mcg for treatment of sever postspinal hypotension
Trial: NCT05126836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05390645
Drug: MFA-370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFA-370 is a treatment with a combination of two approved pharmaceuticals
Trial: NCT06489249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablet
Trial: NCT06489249
Drug: Salsalate 750 MG Oral Tablet [DISALCID]
RxNorm normalized name: salsalate 750 MG Oral Tablet [Disalcid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral salsalate tablet
Trial: NCT05939947
Drug: ALE.F02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
Trial: NCT05939947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.
Trial: NCT05278988
Drug: PRS Regimen V
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRS Regimen V(bedaquiline, delamanid, clofazimine, pyrazinamide)
Trial: NCT05278988
Drug: MDR-TB Treatment Regimen(WHO)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to WHO MDR-TB treatment guidelines (2019)
Trial: NCT04942054
Drug: Part 1
RxNorm normalized name: INSULIN,ASPART 100 UNIT/ML 3ML CART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation cohort
Trial: NCT06519370
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest
Trial: NCT05216341
Drug: OLP-1002
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.
Trial: NCT00657579
Drug: DE-104 ophthalmic solution, low concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00657579
Drug: DE-104 ophthalmic solution, medium concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00657579
Drug: DE-104 ophthalmic solution, high concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05473520
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
Trial: NCT05473520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + standard anti-tuberculous treatment
Trial: NCT06610799
Drug: IBI363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI363 Q3W Oxaliplatin 130 mg/m2，IV，Q3W, Capecitabine ,1000mg/ m2，PO，Bid，d1-14，Q3W
Trial: NCT04723862
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
Trial: NCT04723862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
Trial: NCT05397470
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered BID by mouth along with food.
Trial: NCT05854992
Drug: Acute migraine treatment with any prescribed triptans
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan, treximet (sumatriptan/naproxen combination), zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. No restriction on dose, frequency, duration, or delivery routes.
Trial: NCT06683534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to receive placebo will be administered a standard placebo sugar pill.
Trial: NCT06622499
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the first trial day healthy volunteers are randomized to receive 1 liter of Ringer's lactate either cold (10°C, 50°F), or at room temperature (22°C, 71.6°F) with 100 ml/min. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures.
Trial: NCT05901883
Drug: CEL383
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive CEL383
Trial: NCT05901883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo
Trial: NCT06631547
Drug: The usual head trauma care
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the basic treatment
Trial: NCT06628466
Drug: Nuberol Forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of Life study
Trial: NCT06690398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo administered orally once daily
Trial: NCT04531397
Drug: ACEI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks
Trial: NCT04903808
Drug: Allium Sativum Oil
RxNorm normalized name: Allium sativum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic oil Captain Company (CAP-PHARM)
Trial: NCT06697886
Drug: Antiwei Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
Trial: NCT06697886
Drug: Antiwei Granules Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 3-day treatment period, participants will receive 9 sacks of Antiwei granules. Oral administration, 1 sack (6g) per time, 3 times daily.
Trial: NCT04569227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO daily
Trial: NCT06167707
Drug: SCP-111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide injection 80 mg/mL, 80 mg SC via autoinjector x 1 dose
Trial: NCT06574516
Drug: Ibuprofen 200 mg
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen every 8 hours for three days post operatively
Trial: NCT06711562
Drug: Anti-Infective Drugs
RxNorm normalized name: INVESTIGATIONAL ANTI-INFECTIVE DRUGS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-infective drugs are administered using the traditional clinical dosing regimen, with no interventions.
Trial: NCT05813717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06712771
Drug: VSA003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections
Trial: NCT06712771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections
Trial: NCT04560569
Drug: 3BNC117 Antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120
Trial: NCT05120596
Drug: T3P-Y058-739 (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05296629
Drug: DFD-29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFD-29 (40 mg) extended release capsules
Trial: NCT05296629
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 40 mg capsules
Trial: NCT05296629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT05202379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT05925166
Drug: rhTNFR-Fc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
Trial: NCT06710561
Drug: SPN01 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After each subject was randomly assigned, different doses of SPN01 for Injection (0.02 mg/kg, 0.06 mg/kg, 0.12 mg/kg) were administered intravenously in a single dose.
Trial: NCT06710561
Drug: SPN01 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorectal cancer subjects will receive intravenous injection of SPN01 0.06 mg/kg for a single dose.
Trial: NCT04940390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for STS101
Trial: NCT06450184
Drug: NUPLAZID 34 MG Oral Capsule
RxNorm normalized name: Nuplazid 34 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of Pimavanserin Capsule 34mg
Trial: NCT04828694
Drug: BICX104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erodable implantable pellet containing 1 g naltrexone and 11 mg magnesium stearate.
Trial: NCT05668091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours.
Trial: NCT05905458
Drug: HRS9950 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS9950 tablets, oral, once a week, low dose
Trial: NCT05905458
Drug: HRS9950 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS9950 tablets, oral, once a week, high dose
Trial: NCT05905458
Drug: HRS9950 placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS9950 placebo tablets, oral, once a week.
Trial: NCT04934228
Drug: Hydrochlorothiazide 12.5Mg Tab
RxNorm normalized name: HYDROCHLOROTHIAZIDE 12.5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Hypertension~3. Dose(s): 25 mg/day~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day
Trial: NCT04934228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.